GSK PLC - Director/PDMR Shareholding
GSK plc (the 'Company')
2026 Performance Share Plan Award and 2026 Performance Measures
2026 Performance Share Plan Award
On
Under the terms of the Plan, conditional awards are granted over a specific number of Ordinary Shares or American Depositary Shares ('ADS'), and the percentage of awards that ultimately vests is dependent on the level of achievement against performance targets set by the Remuneration Committee.
The performance period for the awards is the three financial years from
2026 Performance Measures
The awards are based on the following five measures:
|
Performance Measure |
Proportion of each award |
|
Total Sales Growth
|
17.5% |
|
Core Operating Profit Growth |
17.5% |
|
Pipeline Sustainability
|
17.5% |
|
Responsible Business: Composite Scorecard
|
7.5% |
|
Relative Total Shareholder Return (TSR)
|
40% |
Total sales and Core operating profit growth
These targets were set following the Board's annual planning process and consideration of analysts' consensus to ensure that they are sufficiently stretching and support the Committee's aim to incentivise and reward over performance.
|
|
Performance vs Target |
Proportion Vesting
|
|
Below threshold |
< 99% of Target |
Nil |
|
Threshold |
99% of Target |
20%: CEO 25%: CFO / All Others |
|
Target |
100% of Target |
50% |
|
|
103% of Target |
75% |
|
Maximum |
105% of Target |
100% |
Pipeline Sustainability
The Pipeline Sustainability measure focuses on GSK's replenishment of the pipeline and longer-term pipeline performance. For inclusion, a Programme must be either a New Molecular Entity (NME), or a new indication which adds
- Pipeline sales contribution to GSK's long range forecast (LRF) outlook. The target and vesting will each be based on 10-year net risk adjusted sales forecast, e.g., the 2026-2028 target based on the 2035 LRF and vesting based on the 2038 LRF, and
- the Number of Programmes in Phase 2 and 3 and Registration and Approval.
This element of the PSP will only vest, either in full or in part, if at the time of vesting the most recently governed and published 2031 Sales outlook remains at least
Responsible Business: Composite scorecard
The Composite scorecard focuses on all the Responsible Business metrics within the Responsible Business Performance Rating. The rating is reported on in detail in each year's Annual Report with the scorecard providing a balanced assessment of performance against all our Responsible Business priorities.
Performance will be calculated by aggregating the annual performance across all the individual annual metrics within the rating for the 3 years of the PSP performance period.
|
Performance |
Vesting Schedule |
|
70% or more of all metrics are on track |
100% |
|
60% of all metrics are on track |
75% |
|
50% of all metrics are on track |
50% |
|
Less than 50% of all metrics are on track, but progress is being made because at least 50% are either on track, or on track with work to do (the 'threshold' vesting level) |
20%: CEO 25%: CFO / All Others |
|
Less than 50% of all metrics are either on track or on track with work to do, the rest (i.e. more than 50%) are off track |
Nil |
Relative TSR
Performance against our size-adjusted global biopharma peer group of 13 companies will be assessed using a percentile vesting approach. This compares GSK's actual TSR performance with that of our peers.
The median TSR and the upper quintile TSR of the peers is calculated excluding GSK's TSR. GSK's TSR is then compared against the median and upper quintile TSR on an interpolated basis. Threshold performance is at median, and maximum vesting (100%) is achieved for upper quintile performance. Straight-line interpolation determines vesting levels between median and upper quintile.
|
TSR Performance |
Vesting Schedule |
|
Above upper quintile |
100% |
|
Upper quintile |
100% |
|
Between median and upper quintile |
Straight-line interpolation |
|
Median (threshold vesting) |
20%: CEO 25%: CFO / All Others |
|
Below median of peer group |
Nil |
1 See assumptions and basis of preparation related to 2026 guidance, 2021-26 and 2031 Outlooks within GSK's Full-year and fourth quarter 2025 results announcement and GSK's cautionary statement below.
Notes
1. To the extent that each element of a conditional award does not vest at the end of the three-year performance period, it will lapse.
2. The PDMRs in the transaction notifications below were each granted a conditional award under the terms of the GlaxoSmithKline 2017 Performance Share Plan. Awards granted are of Ordinary Shares or ADS.
3. Dividends will accrue on the conditional award of Ordinary Shares or ADS during the performance period but will only vest to the extent that the awards themselves vest at the end of the performance period. These dividends are not included in the figures below.
4. For Executive Directors, the award is subject to an additional holding period of two years (the 'Holding Period') from the normal vesting date, i.e. five years in total. During the Holding Period, the relevant Ordinary Shares or ADS would only be forfeited in the event that the Executive Director was terminated for cause, and the Ordinary Shares or ADS will continue to carry rights to dividend equivalents.
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
463,662 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
Chief Financial Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
196,548 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
President, |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
32,757 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
President, International |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
37,315 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
133,977 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
Chief |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
37,906 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
President, US |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS')
ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
A conditional award of ADS under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
53,433 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
President, Global Product Strategy |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
38,291 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
|
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS')
ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
A conditional award of ADS under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
44,313 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
President, Corporate Development |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
143,579 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
President, Global Supply Chain |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
150,453 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
66,221 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
136,579 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
Chief Scientific Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
247,138 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
SVP & Company Secretary |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
11,800 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
|
|||
|
b) |
Position/status |
PCA of
|
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
11,800 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-02-12 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q4 Results for 2025.
Registered in
No. 3888792
Registered Office:
WC1A 1DG
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE